{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.22","upperLimit":"24.28","value":"7.23"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"description":"EFS is defined as the time from JCAR017 infusion to the earliest of the following events: death from any cause, progressive disease (PD), or starting a new anticancer therapy. Kaplan-Meier (KM) methodology will be used to analyze EFS.\n\nPD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment.\n\nPET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \\> mediastinum but ≤ liver; 4-uptake moderately \\> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.","id":"OG000","title":"Lisocabtagene Maraleucel (JCAR017)"}],"paramType":"MEDIAN","populationDescription":"All participants with PET positive disease who received at least one infusion of JCAR017","reportingStatus":"POSTED","timeFrame":"From first dose to death from any cause, progressive disease (PD), or starting a new anticancer therapy (up to approximately 24 months)","title":"Event-Free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"Months"}